Access to medicines versus access to treatment: the case of type 1 diabetes.
Beran
David
D
International Insulin Foundation, London, England.
McCabe
Ariane
A
Yudkin
John S
JS
D000349:Africa; D002908:Chronic Disease / Q000188:drug therapy*; D003906:Developing Countries / Q000191:economics; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D016527:Drug Costs; D004345:Drug Industry; D018954:Drugs, Essential / Q000191:economics* / Q000600:supply & distribution; D016568:Drugs, Generic / Q000191:economics / Q000600:supply & distribution; D006297:Health Services Accessibility / Q000191:economics* / Q000941:ethics / Q000458:organization & administration; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics* / Q000600:supply & distribution / Q000627:therapeutic use; D007328:Insulin / Q000191:economics* / Q000600:supply & distribution / Q000627:therapeutic use
D018954:Drugs, Essential; D016568:Drugs, Generic; D007004:Hypoglycemic Agents; D007328:Insulin
Lancet. 1997 May 10;349(9062):1347-52
9149696
Bull World Health Organ. 2007 Apr;85(4):279-88
17546309
BMC Health Serv Res. 2006 Feb 24;6:17
16504123
Diabetes Care. 2005 Sep;28(9):2136-40
16123479
Lancet. 2006 Nov 11;368(9548):1689-95
17098088